Analyst Research Report Snapshot

Title:

BIOLINERX - UPDATE ON LEAD PROGRAMMES

Price:

$10.00

Provider:

Edison Investment Research

Date:

06 Feb 2014

Pages:

9

Type:

AcrobatPDF

Companies referenced:

BLRX.TA

Available for Immediate Download
Summary:

BioLineRx plans to start a Phase I study of BL-8040 in stem cell mobilisation, a second indication. This follows the disclosure of promising partial results from its ongoing Phase II study in acute myeloid leukaemia (AML). Meanwhile, the outcome of the sale process involving Ikaria, its commercial partner for BL-1040, is now clear. We maintain our valuation of BioLineRx at $210m, equivalent to $8.9/ADR (basic) or $7.9/ADR (fully diluted).

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.